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Mast cells and basophils are cells that play an important role in the
initiation and control of allergic inflammation in asthma and rhinitis.
This study was undertaken to determine the presence and dynamics
of mast cells and basophils in the nasal and bronchial mucosa of al-
lergic rhinitis patients after segmental bronchial provocation (SBP).
Eight nonasthmatic, grass pollen-allergic rhinitis patients and eight
healthy controls were included. Bronchial and nasal biopsies, as well
 









Immunohistochemical staining was performed for mast cells
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 0.05) in atopic patients after SBP. No significant
changes could be observed in healthy controls. This study shows
that SBP in nonasthmatic allergic rhinitis patients reduces numbers
of mast cells in the nose as a result of enhanced degranulation. At
the same time, there is evidence for an influx of basophils from the
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Asthma and rhinitis, which are considered manifestations of
the atopic syndrome, often coexist (1, 2) and share a common
genetic background (3). Although several studies have dem-
onstrated that asthma and rhinitis are characterized by a simi-
lar inflammatory process (4–7), pathophysiologic interactions
between upper and lower airways are not entirely understood.
It is clear that the condition of the upper airways influences
the lower airways. In allergic rhinitis patients without bron-
chial hyperreactivity (BHR), signs of allergic inflammation of
the lower airways have been found in induced sputum, bron-
choalveolar lavage fluid (BALF), and bronchial biopsy speci-
mens (8–10).
 
Mast cells and basophils are metachromatically staining cells
that are believed to play an important role in the initiation and
control of upper and lower respiratory allergy (11). Both cell
 









RI lead to degranu-
lation of mast cells and release of histamine and proteases,
 
among other effects, characteristic of the early phase of the
allergic immune response (EAR). Mast cells are also sources





 (12). Through the release of mediators, mast cells
can clearly orchestrate the infiltration of leukocytes into sites
of mast cell activation (13). Although basophils comprise a mi-
nor component of the inflammatory cell influx, they are capa-
ble of producing more IL-4 and IL-13 per cell than any other
cell type (14, 15). Therefore, basophils are considered impor-
tant modulators of the allergic immune response. Moreover,
their total number and relative contribution increase during
the late phase of the allergic response (LAR), and correlate
with the severity of disease (16). The pattern of mediator re-






 and the corticosteroid sensitivity of the LAR (17),
indicates that the basophil and not the mast cell is the main
source of histamine in the LAR. An increase in the number of
basophil-like cells in the nasal mucosa has been reported after
nasal allergen provocation (18, 19). In a previous article, we
 









increased in the nasal mucosa of AR patients at 24 h after seg-
mental bronchial provocation (SBP). This indicates that a si-
multaneous LAR may take place in other organs than those
exposed to the allergen (20). Here we report on the contribu-
tion of metachromatic cells to the inflammatory process in
both the challenged lung and in the nose, with special empha-
sis on early allergic events. Bronchial and nasal mucosal bi-
opsy specimens and peripheral blood samples were taken
from a group of nonasthmatic rhinitis patients with an isolated
grass pollen allergy after SBP at a time other than the grass
pollen season. The presence of mast cells was established after













). The presence of baso-
phils was assessed with a novel monoclonal antibody, BB1,






Eight nonasthmatic allergic rhinitis patients (two men and six women,
age range 21 to 31 yr) and eight nonallergic healthy controls (four
men and four women, age range 18 to 29 yr) were included in the
study. Subject characteristics are shown in Table 1. The rhinitis pa-
tients had a history of isolated grass pollen allergy for at least 2 yr, as
confirmed by a positive skin-prick test reaction to grass pollen extract
alone (Vivodiagnost; ALK Benelux BV, Groningen, The Nether-
lands) and not to a panel of 13 other common allergens. The control
subjects had no symptoms or signs of rhinitis and had negative skin-
prick tests. None of the allergic rhinitis patients or controls had a clin-
 




 and a provocative con-












 8 mg/ml. Methacholine was administered according
to a standardized tidal breathing method (22). None of the subjects
smoked or used any medication known to influence the results of the
study. Biopsy specimens were obtained between February and April
1998, before the grass pollen season. None of the patients or control
subjects had an infection of the respiratory tract or any nasal com-
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pants gave informed consent to the study, which was approved by the
 




The study design is outlined in Table 2. Baseline nasal and bronchial














) after SBP. Collection of bronchial biopsy specimens was re-




). Signs and symptoms were scored at the








) on a 10-cm visual analogue
scale (VAS). Symptoms were divided into nasal and ocular com-
plaints (rhinorrhea, watery eyes, nasal itching, sneezing, and nasal
blockage) and pulmonary complaints (wheezing, coughing, shortness
of breath, and decreased exercise tolerance). Upper and lower airway























measured with a Youlten peak nasal inspiratory flow meter (Armstrong

















. The basophil percentage of total white blood cells
was determined by hemocytometric differential cell counting (Sysmex
NE 8000; Sysmex Corporation, Kobe, Japan). IL-5 was measured in
serum with a commercially available enzyme-linked immunosorbent
assay (ELISA) kit, following the instructions of the manufacturer
(Cytoscreen; BioSource International Inc., Camarillo, CA). The mini-




 4 pg/ml, and no
cross-reactivity was found with other cytokines.
 
Bronchial Biopsies and Segmental
Allergen Bronchoprovocation
 
All bronchial biopsy specimens were taken by the same pulmonary
physician (S.E.O.). After intramuscular premedication with atropine
(0.5 mg), oropharyngeal anesthesia was accomplished with topical xy-
locaine spray 1%. The vocal cords, trachea, and bronchial tree were
then anesthetized with oxybuprocaine. A fiberoptic bronchoscope was
introduced into the airway via the oral route, and mucosal biopsy
specimens were taken from the carina of the left upper and lower
lobes. Subsequently, SBP was accomplished with a method described
previously (20). The tip of the bronchoscope (Model BF, type P20 D;
Olympus Optical, Tokyo, Japan) was wedged in the anterior segment
of the right upper lobe (RUL), and 10 ml of 0.9% sterile saline was in-
stilled as a control challenge. Following the control challenge, the
bronchoscope was wedged in a segmental bronchus of the right mid-
dle lobe (RML) and allergen challenge was achieved by instilling 100
BU of grass-pollen extract (Vivodiagnost) made up in 5 ml of sterile
saline. The challenged site was observed for 5 min. In the absence of
local bronchoconstriction, a further 400 BU of allergen in 5 ml of sa-
line was administered, after which the bronchial segment was ob-
served for a further 5 min. The bronchoscope was then quickly re-
moved. After 24 h, each subject underwent a repeat bronchoscopy,
during which biopsy specimens were taken from lobar segments of the
unchallenged left side, the saline-challenged RUL, and the allergen-
challenged RML. The bronchial biopsy specimens were embedded in
Tissue-Tek II Optimal Cutting Temperature (OCT) compound (Sakura












All biopsy specimens of nasal mucosa were taken by the same investi-
gator (G.J.B.) according to the study design as shown in Table 2. First,
local anesthesia was induced by placing a cotton-wool carrier with 50 to
100 mg of cocaine and 3 drops of epinephrine (1:1,000) under the infe-
rior turbinate, without touching the biopsy site. Second, mucosal biopsy
samples were obtained from the lower edge of the inferior turbinate,
about 2 cm posterior to the edge, by using a Gerritsma forceps with a
cup diameter of 2.5 mm. Nasal biopsy specimens were embedded in






















g/ml; clone HM25M; CLB, Amsterdam, The Netherlands), mouse








g/ml; clone B7; Chemicon, Brun-





























































1 31 F 4.00 108 4.99 80 102 40
2 21 M 4.02 85 5.15 79 107 11.8
3 25 F 4.74 126 5.62 84 102 23.6
4 25 M 4.35 94 5.44 80 104 40
5 27 F 3.71 114 4.06 91 100 40
6 23 F 3.91 113 4.54 86 104 40
7 23 F 4.00 122 4.65 86 105 40
8 21 F 4.06 111 4.7 86 100 40
Controls
9 23 F 2.96 82 3.43 86 110 40
10 29 M 5.59 115 7.42 76 108 32.4
11 24 M 4.14 94 4.72 88 101 40
12 28 F 2.52 80 2.67 95 102 40
13 25 F 4.21 112 4.72 89 101 40
14 21 M 5.99 100 6.98 86 102 40
15 20 M 4.81 114 5.44 88 102 9














are presented as percentage improvement compared to initial value). a virtual value of
 










 inspiratory vital capacity.
 

















































 visual analogue scale for scoring nasal and pulmonary
symptoms.
 


































































1 4.00 3.82 235 190 6 37 7 56
2 4.02 4.05 265 250 26 68 52 128
3 4.74 4.34 200 180 0 123 0 35
4 4.35 4.21 270 260 36 16 35 35
5 3.71 3.35 230 220 24 31 46 54
6 3.91 3.94 220 215 13 34 0 47
7 4.00 3.77 250 230 10 27 36 49
8 4.06 3.64 220 220 8 50 12 28
Controls
9 2.96 2.97 120 115 na na na na
10 5.59 5.13 290 185 28 15 36 53
11 4.14 4.10 160 240 4 9 7 6
12 2.52 2.46 230 240 31 68 49 203
13 4.21 4.08 235 205 7 6 19 63
14 5.99 4.69 300 265 8 30 11 43
15 4.81 5.68 180 195 21 24 56 53














 peak nasal inspiratory flow.
Symptoms were individually expressed in millimeters on a 10-cm visual analogue
scale, and a composite score was obtained for nasal complaints (rhinorrhea, watery
eyes, nasal itching, sneezing, and nasal discharge) and pulmonary complaints (wheez-























g/ml; clone BB1; Immunopharmacology Group, Southamp-
ton General Hospital, Southampton, UK). The mAb BB1 recognizes
a unique granule constituent of basophils (21).
 
Double Staining for Tryptase and Chymase
 
Staining was done according to a modified method as previously de-





thick sections on a Reichert–Jung 2800e Frigocut cryostat (Leica,














Before staining, slides were heated to room temperature (RT) and
subsequently dried and fixed in acetone for 10 min at RT. Slides were
then rinsed in phosphate-buffered saline (PBS; pH 7.8) and placed in
a semiautomatic stainer (Sequenza; Shandon, Sewickley, PA). Endog-
enous peroxidase was blocked with 0.1% sodium azide and 0.01% hy-
drogen peroxide in PBS for 30 min. Sections were then rinsed in PBS
for 10 min, incubated with 10% normal goat serum (CLB) and 10%
normal rabbit serum (CLB). Subsequently, slides were incubated with
mouse antibody to human tryptase for 60 min at RT. Sections were
rinsed with PBS for 5 min, incubated with peroxidase (PO)-conjugated
rabbit antimouse (1:200; Sigma) immunoglobulin, rinsed with PBS, and
incubated with PO-conjugated mouse anti-PO antibody (1:200; Sigma)
for 30 min. Slides were incubated with 10% normal mouse serum
(CLB) for 10 min and were then incubated with biotinylated mouse
antibody to human chymase (B7) for 60 min. They were rinsed once
more with PBS for 5 min and incubated with alkaline phosphatase
(AP)-conjugated goat antibiotin antibody (1:50; Sigma) for 30 min.
Next, slides were rinsed with PBS for 5 min and with Tris buffer (0.1 M,
pH 8.5) for 5 min, and were incubated for 30 min in Fast Blue sub-
strate containing levamisole to block endogenous AP enzyme activity.
Sections were then rinsed with sodium acetate (0.1 M, pH 4.6) for 5 min
and incubated with aminoethylcarbazole (AEC; 0.05% in sodium ace-
tate 0.1 M, pH 4.6, and 0.01% peroxide) substrate for 30 min. Follow-
ing this, the slides were rinsed with distilled water and mounted in
glycerin gelatin. Control staining was done with an irrelevant mAb of
the same subclass and at the same protein concentration as the spe-
cific antibody.
 
Single Staining and Tyramide Signal Amplification
 
The mAb stains were developed with the supersensitive immuno-AP
(ss-AP) method as previously described (24). The basophil staining
method differed from the staining method described earlier in the in-
clusion of a tyramide signal amplification (TSA) (NEN Inc., Boston,
MA) step to enhance the BB1 signal. Briefly, tissue fixation was done
as previously described, followed by blocking of endogenous avidin
and biotin with the Vector Blocking Kit, (Vector Laboratories, Burl-
ingame, CA) according to the specifications of the manufacturer. Sub-
sequently, slides were rinsed in PBS (5 min) and incubated with BB1
antibody for 1 h. After rinsing in PBS, endogenous peroxidase was
blocked with azide (0.2%), peroxidase (0.02%), and methanol (50%)
in PBS. TSA was done by subsequent incubation with streptavidin
PBS/bovine serum albumin (BSA) solution (1:100) (NEN Inc.) for 10
min, rinsing with PBS, and incubation with AP-conjugated goat anti-
biotin antibody (1:50, Sigma) for 30 min. This was followed by incuba-
tion in new fuchsin (Chroma, Kongen, Germany) substrate (containing
levamisole to block endogenous AP enzyme activity) for a maximum
of 30 min. The sections were then rinsed in distilled water, counter-
stained with Gill’s hematoxylin, and mounted in glycerin gelatin. Con-
trol staining was done with an irrelevant mAb of the same subclass









apart were counted under blind conditions for each antibody. Bron-





m deep into the lamina propria, along the length of the epi-
thelial basement membrane), and stained cells were counted as previ-
ously described (20). Nasal biopsy sections were divided into epithe-
lium, subepithelium, and lamina propria (total subepithelial mucosa).
Positively stained epithelial and subepithelial cells were counted along
the basement membrane (BM), which had to be undamaged for a
 
length of at least 1 mm before being accepted for evaluation. For lam-




 was required for analysis. Cell
numbers in the subepithelial mucosa were determined as the number




, and those in the epithelium were de-
termined as cells per mm of BM, using an Axioskop 20 microscope









Data were first analyzed with Friedman’s test for several related sam-
ples. In cases of significance, further analysis was done with Wil-
coxon’s test for intragroup analysis and the Mann–Whitney U test for
















All control subjects and allergic rhinitis patients received a to-
tal dose of 500 BU grass pollen solution without exhibiting
any macroscopic bronchoconstriction. An overview of the
















 in the aller-


































11% to 0%) lower than its baseline




9% to 0%) be-
low its baseline value in healthy controls. Although the overall
increase in nasal and pulmonary symptoms was greater in the




, no significant differences were found
in total nasal and pulmonary VAS scores for allergic rhinitis
patients versus controls.
Figure 1. (A) Percentage of peripheral blood basophils in white blood
cell (WBC) count before (T0) and 24 h (T24) after SBP. AR 
 allergic
rhinitis patients; C 
 control subjects. Data are presented as median 
range. *p  0.05. (B) Concentration of hIL-5 (pg/ml) in serum before
(T0) and 24 h (T24) after SBP. AR 
 allergic rhinitis patients; C 
 con-
trol subjects. Data are presented as median  range. *p  0.05.
Braunstahl, Overbeek, Fokkens, et al.: SBP Affects Mast Cell and Basophil Numbers in Allergic Rhinitis 861
Peripheral Blood Parameters
No significant difference in baseline blood basophil percentage
was observed in allergic patients (median: 0.8%; range: 0.3% to
2.0%) as compared with healthy controls (median: 0.75%; range:
0% to 1.4%). At T24, the percentage of blood basophils was sig-
nificantly decreased in allergic patients as compared with base-
line (p 
 0.02; Figure 1a). This was accompanied by a smaller re-
duction in the control group (p 
 0.2). No significant difference
was found between allergic rhinitis patients and controls at T24.
At T0, the concentration of IL-5 in the serum of allergic
rhinitis patients (median: 9.6 pg/ml; range: 0 to 73.6 pg/ml) was
comparable to that of controls (median: 8.3 pg/ml; range: 0 to
31.3 pg/ml). At T24, however, the median concentration of IL-5
in allergic rhinitis patients was increased by threefold over the
baseline concentration (p 
 0.02; Figure 1b). The serum con-
centration of IL-5 in the control group did not change after
SBP, and was significantly lower than the serum concentra-
tions of IL-5 in the allergic rhinitis group (p 
 0.05).
Immunostaining
General description. Three nasal mucosa specimens and four
bronchial biopsy specimens were collected per patient. Of the
112 biopsy specimens, 106 met the criteria for evaluation. In
bronchial biopsy specimens, the median length of evaluable
basement membrane was 3.7 mm (range: 1.1 to 7.8 mm). The
median surface area of subepithelium was 0.37 mm2 (range:
0.11 to 0.78 mm2). Bronchial epithelium and subepithelium could
not be evaluated in five samples. In nasal biopsy specimens, the
median length of evaluable basement membrane was 5.2 mm
(range: 1.1 to 12.5 mm), the median surface area of nasal sub-
epithelium was 0.54 mm2 (range: 0.11 to 1.25 mm2), and the
median surface area of lamina propria was 4.69 mm2 (range:
1.88 to 8.31 mm2). The specified areas could not be evaluated
in one case. A minimal number of seven subjects per subgroup
could be included for every time point.
Bronchial specimens. At T0, the numbers of IgE
, BB1,
tryptase, and chymase cells (phenotypes MCT, MCTC, and
MCC) in bronchial epithelium and subepithelium were low
and not significantly different in the allergic rhinitis patients
and controls (Table 4). At neither T0 nor T24 could changes in
IgE, MCT, MCTC, MCC, and BB1
 cells be detected in con-
trol subjects in any of the tissues studied. In bronchial epithe-
lium of allergic rhinitis patients, only a few mast cells and
BB1 cells (Figure 2) could be detected before and after SBP.
At T24, the epithelial IgE
 cell number tended to be higher in
the unchallenged (p 
 0.05) and saline challenged (p 
 0.1)
segments, and was significantly higher in the allergen chal-
lenged (p 
 0.04) segment of allergic rhinitis patients than of
controls. At T24, the numbers of IgE
 cells and mast cells in
the subepithelium of allergic rhinitis patients were not signifi-
cantly affected. The number of BB1 cells in the bronchial
subepithelium (Figure 3) of allergic rhinitis patients, however,
increased significantly in the allergen challenged segment (p 

0.02), saline control segment (p 
 0.02), and even in the un-
challenged segment (p 
 0.08). At T24, the number of BB1

cells in the bronchial subepithelium was significantly in-
creased in the allergic rhinitis subjects as compared with the
controls for the allergen challenged segment (p 
 0.002) and
saline challenged segment (p 
 0.01), but not for the unchal-
lenged segment (p 
 0.6).
Nasal specimens. As in the bronchial mucosa, only few
chymase, tryptase (Figure 4), or BB1 cells were seen in the
nasal epithelium, of any subject either before or after SBP
(Table 5). At T0, IgE
 cells could be detected in the nasal epi-
thelium, and the numbers of such cells were higher in the al-
lergic rhinitis patients than in controls (p 
 0.06). At T0, the
numbers of IgE cells and MCTC, MCT, and BB1
 cells in the
nasal lamina propria showed no significant differences in the
allergic rhinitis patients and control subjects. The number of
MCC cells, however, was higher in the rhinitis patients than in
the controls at T0 (p 
 0.03).
At T1, no significant changes in cell numbers were found
for mast cells, IgE cells, or BB1 cells in nasal epithelium and
lamina propria of the allergic rhinitis patients as compared
TABLE 4. CELL NUMBERS IN BRONCHIAL SPECIMENS BEFORE (T0) AND 24 h (T24) AFTER SEGMENTAL
BRONCHIAL PROVOCATION
Variable Group Layer T0
T24
UC AC SC
IgE AR Epithelium 0 (0–22) 14 (0–48) 2 (0–29) 3 (0–58)
Subepithelium 21 (0–442) 41 (21–264) 76 (0–128) 138 (32–943)
C Epithelium 0 (0–3) 0 (0–2) 0 0 (0–21)
Subepithelium 15 (0–35) 4 (0–133) 10 (0–245) 10 (0–120)
BB1 AR Epithelium 0 0 (0–1) 0 0
Subepithelium 0 (0–4) 9 (0–144) 88 (22–223)* 25 (5–350)*
C Epithelium 0 0 0 0
Subepithelium 0 (0–4) 5 (0–16) 5 (0–88) 2 (0–33)
MCC AR Epithelium 0 0 (0–3) 0 0
Subepithelium 2 (0–28) 0 (0–43) 0 (0–21) 4 (0–143)
C Epithelium 0 0 0 (0–8) 0 (0–3)
Subepithelium 0 (0–8) 0 (0–3) 0 (0–2) 2 (0–5)
MCTC AR Epithelium 0 (0–33) 0 (0–3) 0 (0–5) 0
Subepithelium 36 (0–141) 42 (0–126) 31 (4–131) 33 (0–81)
C Epithelium 0 (0–3) 0 (0–3) 0 (0–3) 0 (0–8)
Subepithelium 14 (0–79) 8 (0–184) 15 (0–89) 27 (0–265)
MCT AR Epithelium 1 (0–10) 8 (0–55) 0 (0–22) 0 (0–24)
Subepithelium 111 (0–622) 161 (28–351) 139 (25–323) 74 (0–326)
C Epithelium 0 (0–19) 0 (0–13) 8 (0–31) 9 (0–36)
Subepithelium 127 (8–203) 56 (10–140) 151 (0–414) 110 (0–300)
Definition of abbreviations: AC
 allergen challenged right middle lobe; AR 
 allergic rhinitis patients; C 
 control subjects; SC 
 saline
challenged right upper lobe; UC 
 unchallenged left lung.
Data are presented as median  range.
*p  0.05 (Wilcoxon’s signed ranks test).
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with baseline numbers. At T24, however, the numbers of MCC
(p 
 0.02) and MCTC (p 
 0.04) cells in the nasal lamina pro-
pria of the allergic rhinitis patients were significantly de-
creased (Figures 5a and 5b). In contrast, the numbers of MCT
and IgE cells remained stable, whereas that of BB1 cells
was significantly increased (p 
 0.01; Figure 5c). At T24, the
BB1 cell number in the nasal subepithelium (p 
 0.01) and
lamina propria (p 
 0.02) was significantly higher in allergic
rhinitis patients than in controls. No significant increases from
baseline were seen for IgE, mast cell, or BB1 cell numbers
in healthy controls at either T1 or T24.
Comparison of Cell Counts in Upper and Lower Airways
At T0, IgE
 cell numbers were significantly higher in nasal ep-
ithelium (Table 5) than in bronchial epithelium (Table 4) in
the allergic rhinitis patients (p 
 0.02). In the controls, IgE
cells were predominantly present in nasal epithelium as com-
pared with bronchial epithelium (p 
 0.02), but cell counts
were lower than in the allergic rhinitis subjects. In the subepi-
thelium there was no difference between the number of IgE
cells in either the nose or the bronchi of the allergic rhinitis pa-
tients and control subjects. At T0, BB1
 cells could hardly be
detected in either nasal or bronchial mucosa of the two study
groups. At T24, however, the influx of BB1
 cells was much
higher in the bronchial subepithelium than in the nasal subepi-
thelium (p 
 0.04) of the allergic rhinitis patients, whereas no
difference was found in the control subjects. There was a clear
difference in the relative distribution of chymase and
tryptase cells between nasal and bronchial mucosa. In the
bronchi, MCT was the predominant cell type (74% in atopic
subjects and 89% in controls), followed by MCTC (23% in
atopic subjects versus 10% in controls) with almost no MCC
cells (3% in atopic subjects versus 1% in controls). In contrast,
MCTC cells were the most abundant cell type in the nose (79%
in atopic subjects and 89% in controls), followed by MCC cells
(19% in atopic subjects and 5% in controls), and with very few
MCT cells (3% in both groups). At T24, the percentage of MCT
cells increased significantly in the nasal subepithelium (p 

0.04) and to a lesser extent also in the bronchial subepithelium
(p 
 0.2) of allergic rhinitis patients, at the expense of MCTC
and MCC cells.
DISCUSSION
In this study, we were able to demonstrate changes in nasal
mast cell and basophil numbers in nonasthmatic allergic rhinitis
patients at 24 h after SBP. Furthermore, we found an influx of
basophils into the bronchi of these nonasthmatic allergic rhin-
itis patients at 24 h after SBP. This occurred not only in chal-
lenged but also, albeit to a lesser extent, in saline challenged
and unchallenged segments. In addition to these inflamma-
tion-related effects, we noticed a sustained decrease in FEV1
after SBP in subjects with allergic rhinitis. In a previous study,
we demonstrated that SBP in allergic rhinitis patients induced
eosinophilia in the blood and mucosal inflammation charac-
terized by increased numbers of eosinophils, and of IL-5 and
eotaxin cells in both upper and lower airways (18). These
data suggest a more generalized effect of local allergen depo-
sition.
Granule secretion by mucosal mast cells, and the influx of
basophils from blood into tissue, have been associated with
disease activity in the upper and lower airways of patients with
allergic rhinitis and asthma (16, 18, 25–27). Since these two
cell types are important for initiation and modulation of the
allergic reaction (11, 14, 15), we studied the dynamics of mast
cells and basophils in the nasal mucosa after allergen provoca-
tion in a distant and “downstream” organ.
In the nasal mucosa, the numbers of chymase (MCC) and
tryptase/chymase (MCTC) mast cells decreased significantly,
whereas the numbers of BB1 cells increased significantly in
allergic rhinitis patients at 24 h after SBP. In contrast to the
Figure 2. Bronchial biopsy specimens of a challenged allergic subject
stained immunohistochemically for BB1 cells and counterstained with
hematoxylin. Original mangnification 200.
Figure 3. Number of BB1 cells in subepithelial layer before (T0) and
24 h (T24) after SBP. AC 
 allergen challenged right middle lobe;
AR 
 allergic rhinitis patients; C 
 control subjects; SC 
 saline chal-
lenged right upper lobe; UC 
 unchallenged left lung. Data are pre-
sented as median  range. *p  0.05, **p  0.01.
Figure 4. Nasal biopsy sections of an allergic subject showing immu-
noreactivity for mast cells at T0. Counterstained with methyl green.
Original magnification: 400.
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changes found in the nose, the number of mast cells in the
bronchial subepithelium, which are predominantly tryptase
(24, 28, 29), did not change significantly after SBP. A possible
explanation for the relatively stable number of tryptase cells
in the nasal and bronchial mucosae could be the influx of
tryptase basophils from the peripheral blood into the bron-
chial mucosa (30).
Discrepancies in mast cell counts in different studies, prob-
ably caused by different methods for detecting of mast cells,
have led to various opinions about mast cell dynamics. Trans-
mucosal migration of mast cells into the epithelium has been
suggested as a possible mechanism for an increase in epithelial
mast cells after allergen exposure (5, 31). Degranulation has
been proposed and demonstrated by other authors, and could
also contribute to changes in mast cell numbers in the nasal
and bronchial mucosae (10, 26, 32, 33). Immunohistochemical
analysis of mast cells is hampered by the lack of a universal
mast cell membrane-associated marker. In our study we found
no indication of a redistribution of mast cells in nasal and
bronchial mucosae at either an early (T1) or a late (T24) time
point. Therefore, degranulation is a more likely mechanism
for the sudden decrease in MCC and MCTC cells in the nasal
lamina propria of allergic rhinitis patients after SBP, whereas
the number of IgE cells remains stable. Degranulation of
mast cells in the nose after SBP occurred at a relatively late
time point as compared with that found in experiments after
nasal allergen challenge. KleinJan and coworkers demon-
strated an increase in the number of basophils and a reduction
in mast cell numbers in nasal mucosa of allergic rhinitis sub-
jects within 1 h after nasal allergen provocation (28). In our
study, no changes in the number of nasal mast cells or baso-
phils were seen at 1 h after SBP. At T24, however, more than
50% of MCTC cells in the nasal lamina propria of allergic rhin-
itis patients (as compared with only 10% in controls) had lost
their granule contents, which is in accordance with findings
during natural exposure (26). Lozewicz and Wagenmann have
shown that unilateral nasal allergen challenge results in an im-
mediate reduction in the number of stainable mast cells (34)
and in a delayed increase in basophil numbers and histamine
production in the contralateral unstimulated nostril (35). Loz-
ewicz and Wagenmann speculated that a neural reflex mecha-
nism was most likely to contribute to mast cell degranulation
in the unchallenged nostril. The delayed effect on nasal mu-
cosal mast cells that we see in our model, however, is more
suggestive of a systemic allergic response.
In allergic rhinitis patients, we found a decreased number
of basophils in the peripheral blood at 24 h after SBP. The de-
crease in circulating basophils at this time point could have
been the result of active migration and redistribution of these
cells from the blood to the affected tissue (16). Moreover, we
detected increased expression of IL-5 in the serum of allergic
rhinitis patients after SBP, which suggests that a systemic al-
lergic response is triggered. Cytokines such as IL-5, but also
IL-1, IL-3, granulocyte–macrophage colony-stimulating factor
(GM-CSF), stem-cell factor, nerve growth factor, histamine-
releasing factor, and interferon- are capable of priming baso-
phils (36). Both IL-3 and GM-CSF were undetectable in se-
rum samples in our study (data not shown). Comparable serum
IL-5 results have been demonstrated in patients with allergic
asthma after bronchial allergen provocation (37) and natural
exposure to allergen (38). Furthermore, nasal provocation with
methacholine in asthmatic patients with rhinitis resulted in an
TABLE 5. CELL NUMBERS IN NASAL SPECIMENS BEFORE (T0) AND 1 h (T1) AND 24 h (T24) AFTER
SEGMENTAL BRONCHIAL PROVOCATION
Variable Group Layer T0 T1 T24
IgE AR Epithelium 34 (0–140) 13 (0–215) 6 (0–42)
Subepithelium 106 (9–1,211) 157 (19–794) 39 (0–282)
Lamina propria 74 (6–255) 71 (14–192) 46 (5–88)
C Epithelium 4 (0–20) 1 (0–11) 1 (0–24)
Subepithelium 32 (10–55) 29 (3–168) 16 (0–34)
Lamina propria 14 (6–40) 12 (8–34) 10 (2–28)
BB1 AR Epithelium 0 0 (0–1) 0
Subepithelium 1 (0–2) 0 (0–1) 4 (1–12)*
Lamina propria 1 (0–5) 2 (0–3) 7 (3–14)*
C Epithelium 0 0 (0–1) 0 (0–1)
Subepithelium 1 (0–1) 1 (0–1) 1 (0–9)
Lamina propria 1 (0–5) 1 (0–4) 2 (0–10)
MCC AR Epithelium 0 (0–16) 0 (0–6) 0
Subepithelium 29 (8–86) 22 (11–45) 15 (0–179)
Lamina propria 18 (5–48) 11 (3–21) 3 (1–25)*
C Epithelium 0 0 0
Subepithelium 9 (0–55) 6 (2–59) 5 (1–19)
Lamina propria 4 (1–27) 5 (1–47) 3 (0–15)
MCTC AR Epithelium 0 (0–14) 1 (0–27) 0 (0–5)
Subepithelium 235 (54–694) 449 (189–555) 118 (0–451)
Lamina propria 92 (22–178) 114 (77–137) 42 (0–111)*
C Epithelium 0 (0–15) 0 0
Subepithelium 228 (46–540) 223 (80–431) 179 (0–324)
Lamina propria 105 (47–185) 95 (56–127) 89 (0–172)
MCT AR Epithelium 0 (0–7) 4 (0–9) 0 (0–15)
Subepithelium 5 (0–40) 11 (0–123) 9 (0–26)
Lamina propria 2 (0–15) 2 (0–11) 2 (0–6)
C Epithelium 0 0 0 (0–3)
Subepithelium 6 (0–23) 3 (0–78) 3 (0–45)
Lamina propria 2 (1–6) 4 (0–11) 1 (0–13)
Definition of abbreviations: AR 
 allergic rhinitis patients; C 
 control subjects.
Data are presented as median  range.
* p  0.05 (Wilcoxon’s signed ranks test).
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increase in lower airway resistance that could be blocked by
premedication of the nasal mucosa with phenylephrine (39).
This is also suggestive of a systemic effect of inflammatory
mediators in the induction of lower airway resistance. An-
other possible interaction mechanism could be systemic aller-
gen absorption, as was suggested by Kontou-Karakitsos and
colleagues in the early 1970s (40). However, the allergen we
used, grass pollen, has a much higher molecular weight than
the antigen fragments used in the peanut extract in their study.
Therefore, we find it less plausible that grass pollen particles
cross the mucosal barrier and merge in the blood.
It is highly unlikely that the methodologic approach used in
our study would contribute to a systemic allergic response.
Bronchoscopy and biopsy per se do not result in generalized
bronchial inflammation (41). To minimize the intraluminal
spread of antigen from the allergen-challenged segment to
other segments, the bronchoscope in our study was held in the
wedged position. It is also very unlikely that allergen spilled
into the nose after SBP, since bronchoscopy was performed
via the oral route and did not lead to excessive coughing. This
is supported by a small study that addressed the issue of cross-
contamination of the nose and lungs with a radioactive tracer
(42). In this pilot study, a radionuclide was placed broncho-
scopically into the bronchial tree in four patients, and was still
clearly visible in the same position after 24 h, suggesting that
contamination of the nose through intraluminal spread is un-
likely to take place (42).
On the basis of our results, we hypothesize that allergic
rhinitis patients without bronchial hyperresponsiveness can
express “asthma-like” symptoms and inflammation. However,
the dose of allergen required to initiate an allergic response in
the bronchi is probably higher in allergic rhinitis patients than
in patients with clinical asthma. Apparently, such a dose is not
encountered during natural exposure to allergen. Moreover,
other factors, such as the type of inhalant allergy and the dura-
tion and severity of exposure, are important in this context
(43). We also found that SBP influences the number of stain-
able mast cells and basophils in the upper airways of allergic
rhinitis patients. We speculate that enhanced production of in-
flammatory mediators at the site of allergen provocation leads
to a more generalized effect on metachromatic cells through-
out the respiratory system and the blood.
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